Funding & Businessbiotechstartup fundingdrug repurposing

Biossil raises $70M to revive failed drugs

|
6.9
Relevance Score
Biossil raises $70M to revive failed drugs

Biossil exits stealth with $70 million USD to give failed medicines a second chance. The Toronto-based biotech startup launched publicly to focus on rescuing previously unsuccessful drug candidates. It counts OpenAI, Founders Fund, and Staircase Ventures as backers.

Key Points

  • 1Biossil secures $70 million to revive failed medicines and accelerate drug-rescue efforts
  • 2Backers include OpenAI, Founders Fund, and Staircase Ventures, signaling high-profile investor interest
  • 3Toronto-based exit from stealth underscores growing biotech funding and cross-sector investment activity

Scoring Rationale

A notable mid-stage funding event with prominent investors, important for those tracking biotech funding and AI-related investment trends.

Practice interview problems based on real data

1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.

Try 250 free problems